pharma · Head and Neck Neoplasms · Rheumatoid Arthritis
Chinese University of
Chinese University of Hong Kong
Chinese University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor, Essential Hypertension, Primary Esophageal Motility D
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 42
- Drugs
- 55
- Patents
- 0
Baricitinib 4 MG
Approved · small molecule · Rheumatoid Arthritis
Baricitinib 4 MG for Rheumatoid Arthritis is a Approved program (small_molecule) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).
Internal code JAKi
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chinese University of Hong Kong
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Rheumatoid Arthritis
- Status
- active
- Trials
- 1